Increased dose of echinocandins for invasive fungal infections: Bonanza for the patient or the pharmaceutical industry?

Bone Marrow Transplantation

Volumn 39, Issue 3, 2007, Pages 129-131

  Chandrasekar, P H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POLYENE; PYRROLE DERIVATIVE; VORICONAZOLE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ASPERGILLOSIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDITORIAL; ESOPHAGUS CANDIDIASIS; FEBRILE NEUTROPENIA; FUNGICIDAL ACTIVITY; GRAFT RECIPIENT; HUMAN; INVASIVE CANDIDIASIS; MONOTHERAPY; MYCOSIS; NEPHROTOXICITY; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ANTIBIOTICS, ANTIFUNGAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INDUSTRY; FUNGAL PROTEINS; HUMANS; MYCOSES; PEPTIDES, CYCLIC;

EID: 33846607378     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705563     Document Type: Editorial

References (16)

1. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW et al. Voriconazole vs Amphotericin B for the primary treatment of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
2. Stone JA, Holland SD, Wickersham PJ, Sterrett A, Schwarz M, Bonfiglio C et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy man. Antimicrob Agents Chemother 2002; 46: 739-745.
3. Betts RF, Rotstein C, Talwar D, Nucci M, Dewaele J, Arnold L et al. Micafungin vs caspofungin in the treatment of candidimia/invasive candidiasis. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, 2006 (Late Breaker Session).
4. Reboli A, Rotstein C, Pappas P, Schranz J, Krause D, Walsh T. Anidulafungin vs fluconazole for treatment of candidemia and invasive candidiasis. 45th Interscience Conference on Antimicrobial Agent and Chemotherapy, Washington, DC, 2005 (Abstract #M-719).
5. Kartsonis NA, Saah AJ, Joy Lipka C, Taylor AF, Sable CA. Salvage therapy with caspofungin for invasive aspergillosis: Results from the caspofungin compassionate use study. J Infect 2005; 50: 196-205.
6. Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C et al. Micafungin (FK463) alone or in combination with other systemic antifungal agents for the treatment of acute invasive aspergillosis. J Infect 2006; 53: 337-349.
7. Kartsonis N, Teppler H, Ngai A, Bourque M, White M, Williams-Diaz A et al. Efficacy and safety of higher doses of caspofungin. Trends in Medical Mycology. Berlin, Germany, 2005 (Abstract #P-027).
8. Sirohi B, Powles RL, Chopra R, Russell N, Byrne JL, Prentice HG et al. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 38: 47-51.
9. Buell D, Koranda L, Drake T, Fisco C. Alternate drug dosing of micafungin in the treatment of esophageal candidiasis. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005 (Abstract #M-719).
10. Perea S, Gonzalez G, Fothergill AW, Kirkpatrick WR, Rinaldi MG, Patterson TF et al. In vitro interaction of caspofungin acetate with voriconazole agains clinical isolates of Aspergillus sp. Antimicrob Agents Chemother 2002; 46: 3039-3041.
11. Petraitis V, Petraitiene R, Sarafandi AA, Kelaher AM, Lyman CA, Casler HE et al. Combination therapy in treatment of experimental pulmonary aspergillosis: Synergistic interaction between an antifungal azole and an echinocanchin. J Infect Dis 2003; 187: 1834-1843.
12. Meletiadis J, Petraitis V, Petraitiene R, Lin P, Stergiopoulou T, Kelaher AM et al. Triazole-polyene antagonism in experimental pulmonary aspergillosis: In vitro and in vivo correlation. J Infect Dis 2006; 194: 1008-1018.
13. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 797-802.
14. Kubin CJ, Lukose T, Logan A, Sheth N, Sobieszczyk ME, Ramos L et al. Impact of primary combination therapy on outcomes in invasive aspergillosis. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, 2006 (Abstract #M-899).
15. Safdar A, Rodriguez G, Rolston KVI, O'Brien S, Khouri IF, Shpall EJ et al. High-dose Caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 39: 157-164.
16. Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentration. Antimicrob Agents Chemother 2004; 48: 3407-3411.